

CERTIFICATE

OF REGISTRATION FOR PRN:41360

This certifies your registration within the period 01 April 2025 to 31 March 2026 in UK
NEQAS for Leucocyte Immunophenotyping for the scheme(s) listed below:

This information is correct at the date of issue. Registration in UK NEQAS LI programmes is neither an indication of active participation nor quality of performance. Information on these must be obtained directly from the head of laboratory.

Flow Cytometry Programmes

- Measurable Residual Disease for AML by Flow Cytometry
- Paroxysmal Nocturnal Haemoglobinuria

Molecular Haemato-Oncology programmes

- BCR::ABL1 and AML Translocation Identification
- BCR::ABL1 Kinase Domain Variant (Mutation) Status
- BCR::ABL1 Major Quantification
- BCR::ABL1 Minor Quantification
- BRAF p.Val600Glu (V600E) Mutation Status for Hairy Cell Leukaemia
- FLT3 Mutation Status
- IG/TCR Clonality Status
- KIT p.Asp816Val (D816V) Mutation Status for Mast Cell Disease
- Lymphoid Gene Panels
- Lymphoplasmacytic Lymphoma / Waldenstrom Macroglobulinaemia
- Measurable Residual Disease for AML by Molecular Methods
- Myeloid Gene Panels
- Myeloproliferative Neoplasms Diagnostic Testing
- NPM1 Mutation Status
- Paediatric Acute Leukaemia Translocations

Participant Address:

MII Mvz Gmbh

Munich

Germany

Date of Issue:

21/04/2026



Mr Stuart Scott
Director

The schemes listed may not all be included in the scope of accreditation. Full details are available on the UKAS website – www.UKAS.com

